

Index

Page numbers followed by *f* denotes a figure and the letter *t* denotes a table

A

- Abacavir, 331, 331f
- Absorption, distribution, metabolism, and elimination (ADME), 17
- SARs and, 320–323, 321f, 322f, 324t
- Acetaminophen
- conjugation of, 283f
- glutathione conjugation of, 291–292, 291f
- N*-oxidation of, 265, 265f
- sulfate conjugation of, 287f
- Acetazolamide, 337
- Acetic acid, 148f
- for organic salts, 137t
- Acetohexamide, 279f
- Acetone, 150
- Acetonide, 150, 150f
- Acetylation, 292–293, 292f–294f
- Acetylcholine, 18–19, 19f
- conformational isomers of, 230, 231f
- homologation and, 339, 340f
- neostigmine and, 170–171, 171f
- Acetylcholinesterase
- neostigmine and, 170–171, 171f
- phosphorylation of, 172, 172f
- Acidic functional groups, 26–27, 27f
- in amino acids, 177–178, 177f
- ARBs and, 328f
- drug interactions and, 326
- in enzymes, 177–178, 177f
- Henderson-Hasselbalch equation for, 88–90, 89f
- identification of, 52–61
- ionization of, 110, 174–175, 175t
- pK_a of, 71–72, 72f, 86–87
- in proteins, 177–178, 177f
- salts from, 75–76, 75f, 136–137, 137t
- therapeutic significance of, 72–76, 73f–75f
- Active conformation, 233
- Acylation, 168–171, 169f–171f
- Acyl chloride, 271f
- Acyl group, covalent bonds and, 168–171, 169f–171f
- Adenine, 12, 13t
- Adenosine, 288f
- Adenosine diphosphate (ADP), 173
- Adenosine monophosphate (AMP), 335, 336f
- α adrenergic receptors, 31, 31f
- diastereomers of, 225, 225f
- homologation and, 338
- β adrenergic receptors, 31, 317, 372–375
- diastereomers of, 225, 225f
- homologation and, 338
- Adverse drug reactions
- with acidic functional groups, 75
- of heparin, 115–116
- SARs and, 323–326, 325f, 326f
- Alanine, 16, 38, 217
- binding interactions of, 196t
- Albumin, 73
- Albuterol, 31, 31f
- aliphatic amines and, 63–64, 64f
- enantiomers of, 216, 221, 221f
- hydroxyl group and, 266–268, 266f–268f
- oxidation of, 266–267, 266f
- Alcohol dehydrogenase (ADH), 248–249, 266–268, 266f, 267f
- Aldehyde
- carbonyl group of, 20
- charge transfer reactions of, 195f
- electron withdrawing functional groups of, 23, 24f
- ketone reduction and, 272f
- oxidative deamination of, 258
- reduction of, 272–273, 272f, 273f
- sugars and, 5
- Aldehyde dehydrogenase (ALDH), 248–249, 266–268, 266f–268f, 272f
- Aldoses, 5
- Alendronate sodium, 74f
- Alendronic acid, 140, 141f
- Alicyclic amines, 62–64, 63f, 64f, 175t
- Alicyclic carbon, 256–257, 256f, 257f
- Alicyclic rings, 140f
- geometric isomers of, 226–227, 227f
- lipophilic functional groups and, 30, 30f
- numbering of, 4
- Aliphatic amines, 62–64, 63f, 64f
- ionization of, 175t
- pK_a of, 71t
- Aliphatic carbon, 253–257, 254t, 255f–257f
- Aliphatic chains, 189f, 190–192, 190f
- Aliphatic hydroxyl groups, 60
- Aliphatic rings, 226–227
- Aliskiren, 359–362
- Alkenes, 252, 252ff, 253f

- Alkylation, 168, 168f
- Alkyl chains, 30, 30f, 140f
- Alkyl group
charge transfer interactions of, 194f
electron donating functional groups and, 23
nitrogen and, 62
- Alpha/beta (α/β) designation, 7, 8
- Alpha (α) designation, 6–9, 7f
for glycosidic bonds, 9, 9f
- Alprostadil, 52–53, 53f
- Amantadine, 263, 263f
- Amide group, 140f
carbonyl group of, 20
charge transfer reactions of, 195f
electron withdrawing functional groups of, 23, 24f
as hydrogen bond acceptor, 183f, 186f
as hydrogen bond acceptor/donor, 183f
hydrolysis of, 278–279
nitrogen and, 69, 70
oxidation of, 258–265, 259f, 260f, 262f–265f
- Amidine group, 66–67, 66f, 140f
ionization of, 175t
 pK_a of, 71t
resonance delocalization of, 67
- Amines, 140f. *See also* Aromatic amines
biological target selectivity and, 31
charge transfer interactions of, 194f
in gentamicin, 135
ion-dipole interaction with, 131
methylation of, 294, 295
oxidation of, 258–265, 259f, 260f, 262f–265f
 pK_a and pH of, 99
- Amino acids
acidic functional groups in, 177–178, 177f
basic functional groups in, 176, 176f
binding interactions of, 196t
conjugation of, 281t, 288–290, 288f, 289f
enantiomers of, 217
functional groups on, 36–40, 37f
ionic bonds of, 176, 176f
peptides from, 10–12, 10f
- Amino terminus, 10, 11f
- Amiodarone, 136f
- Amitriptyline, 227–228, 227f, 261, 262f
- Amlodipine, 361
- Amoxicillin, 19, 19f, 150–151, 151f
- Amphetamine, 259f
- Ampicillin, 7f, 19, 19f, 150–151, 151f
- Amrinone lactate, 132f
- Angiotensin converting enzyme (ACE)
aliskiren and, 359–360
complexation and, 199, 199f
enalaprilat and, 12
inhibitors, 319–320, 320f
tripeptides and, 11
- Angiotensin I, 11, 12f
- Angiotensin II, 11
- Angiotensin II receptor blockers (ARBs), 327–329, 328f, 335–336
- Aniline group, 140f, 194f. *See also* Aromatic amines
- Anomeric carbon, 7
- Anomers, 7
- Antacids, 117
- Antihistamines, 325f
- Antivirals, 18
- Arginine, 40
binding interactions of, 196t
cation- π interaction of, 193
guanidine group and, 67, 67f, 116
ionic bonds of, 176, 176f
- Aripiprazole, 362–364
- Aromatic amines, 64–65, 64f, 65f
of bimatoprost, 143
as hydrogen bond acceptor/donor, 183f
ionization of, 175t
 pK_a of, 71t, 92
sulfate conjugation and, 286, 287f
- Aromatic heterocycles
ionization of, 175t
nitrogen in, 68–69, 68f, 69f
 pK_a of, 71t
- Aromatic hydroxylation, 250–252, 251f, 252f
- Aromatic nitrogen, 258–265, 259f, 260f, 262f–265f
- Aromatic rings, 140f
aryl-aryl stacking interactions of, 192–193, 192f, 193f
charge transfer interactions of, 193–195, 194f, 195f
electron donating functional groups and, 23, 23f
homologation and, 339
for hydroxyl group, 58–60, 58f, 59f
lipophilic functional groups and, 30, 30f
of methylsalicylate, 114
mixed-function oxidases of, 246
of nitrile group, 20, 21f
oxidation of, 250–252, 251f, 252f
of phenolic group, 20
 pK_a and pH of, 99
position designation for, 4–5
van der Waals interactions of, 189, 189f, 190–192, 190f
- Aryl-aryl stacking interactions, 192–193, 192f, 193f
- Asparagine, 40
binding interactions of, 196t
dipole-dipole interactions of, 181

Aspartic acid, 39
 binding interactions of, 196t
 histidine and, 177, 177f

Aspirin
 acylation of, 170, 170f
 covalent bonds of, 166, 167f
 hydrolysis of, 275

Asthma, 17–18, 31, 317, 338

Atenolol
 oxidative *N*-dealkylation of, 260, 261
 SARs of, 318f

Atomoxetine
 cation– π interaction of, 193, 193f
 conjugation of, 283f
 oxidative deamination of, 259f

Atorvastatin, 138t, 299–300

ATP, methylation of, 295, 295f

Azide, 186f, 187

Azo group, 273–274, 274f

B

Baclofen, 259f

Balsalazide, 273, 273f

Basic functional groups, 26–27, 27f
 in amino acids, 176, 176f
 drug interactions and, 326
 Henderson-Hasselbalch equation for, 88–90, 89f
 identification of, 52–72
 ionization of, 110, 174–175, 175t
 pK_a of, 71–72, 74f, 86–87
 resonance delocalization, 67
 salts from, 75–76, 75f, 136–137, 137t
 therapeutic significance of, 72–76, 73f–75f
 thioridazine and, 128

Beclomethasone dipropionate, 149, 149f, 324t

Benign prostatic hyperplasia (BPH), 319

Benzimidazole rings, charge transfer interactions of, 194f

Benzodiazepines, 65, 65f

Benzoic acid, 148f

Benzothiazole rings, 194

Benzoxazole rings, 194f

Benzotropine, 187, 187f

Benzylic carbon, 253–256, 255f

Berg, J. M., 13

Beta (β) designation, 6–9, 7f

Bethanechol, 98

Bimatoprost, 139, 143, 143f

Binding interactions, 3–4. *See also specific bond types*
 of biological targets, 195–196, 196t
 SARs and, 316–320, 317f, 318f, 320f

Bioisoteres, 331–337

Bioisoteric replacement, 334

Biological targets
 active conformation of, 233
 acylation of, 170–171, 171f
 binding interactions of, 195–196, 196t
 covalent bonds and, 167
 functional groups and, 31, 31f, 36
 pharmacodynamic effects and, 17
 pK_a and pH and, 114
 stereochemistry with, 175
 steric effects with, 175

Biopolymers, 17

Bisphosphonate, 186f

Boat conformation, 232, 232f

Bonds. *See* Binding interactions

Brentuximab vedotin, 344, 345f

Brimonidine, 67, 67f

Brimonidine tartrate, 132f

Bromine, 22, 22f, 179t, 180

Busulfan, 24

Butorphanol tartrate, 75f

C

Cahn, Robert, 217

Calcium hydroxide, 129, 137t

Candesartan, 147, 147f

Candesartan cilexetil, 147, 147f, 276, 277f

Captopril, 60, 60f
 complexation of, 199, 199f
 Henderson-Hasselbalch equation for, 95, 96
 methylation of, 296f
 oxidation of, 268–270
 pH and pK_a of, 91, 92, 95, 96
 SARs of, 319–320, 320f

Carbamates
 as hydrogen bond acceptor, 183f
 as hydrogen bond acceptor/donor, 183f
 hydrolysis of, 279f
 isavuconazole and, 344, 344f
 nitrogen and, 69–70

Carbidopa, 52–53, 296f

Carbinolamine
 isavuconazole and, 344, 344f
 oxidative deamination of, 258

Carbon
 chirality of, 210–213, 211f
 electronegativity of, 179, 179t, 180
 mixed-function oxidases of, 246
 oxidation of, 253–257, 254f–257f
 van der Waals interactions of, 189f, 190–192, 190f

- Carbonic anhydrase
 sulfonamide group and, 335, 337f
 thiazides and, 116, 116f
- Carbonyl group
 chirality of carbon and, 211
 mixed-function oxidases of, 246
 nitrogen and, 70
 oxidation of, 254–255, 255f
 pH and pK_a of, 107
 resonance of, 20, 21f
- Carboprost tromethamine, 137t
- Carboxylic acid
 as acidic functional group, 27f, 52–53, 53f
 amino acid conjugation and, 288, 290
 ARBs and, 329
 in cefepime, 135
 complexation of, 199, 199f
 electron donating functional groups and, 23, 23f
 esters of, 147, 147f
 as functional group, 18
 of furosemide, 185, 185f
 Henderson-Hasselbalch equation for, 88–90, 89f
 hydrolysis and, 277
 hydroxyl group and, 74, 266–268, 266f–268f
 ionic bonds of, 32, 114
 ionization of, 175t
 ketone reduction and, 272f
 for lipid solubility, 148, 148f
 methylene group and, 177
 nonclassical isosteres of, 337t
 noncovalent bonds of, 174
 oxidation of, 266–267, 266f
 oxidative dehalogenation and, 271f
 PABA and, 115, 115f
 in peptides, 10
 pH and pK_a of, 71t, 101, 103, 114
 prodrug conversion of, 341
 resonance delocalization of, 67
 resonance of, 20
 tetrazole rings and, 58, 58f
- Carboxyl terminus, 10–11, 11f
- Catechol-*O*-methyltransferase (COMT), 294, 296
- Catechol rings, 251–252, 252f
- Catechols, 295, 296
 nonclassical isosteres of, 337t
- Cation- π interaction, 193, 193f
- Cefepime, 134–135, 135f
- Cefoxitin, 33, 33f
 acylation of, 169, 169f
 covalent bonds of, 167, 167f
- Cefprozil, 364–367
- Celecoxib, 56, 56f
- Cephalexin, 33, 33f, 275, 276f
- Cephalosporins, 33, 33f
 covalent bonds of, 167
 drug interactions with, 325
- Ceritinib, 69, 69f
- Cetirizine, 52–53, 53f, 325f
- Chain branching, 339–341, 341f
- Chair-chair inversion, 232, 232f
- Chair conformation, 232, 232f
- Charge transfer interactions, 193–195, 194f, 195f
- Chelation, 197–199, 197f, 198f
 drug interactions and, 325, 325f
- Chemical antagonism, ionization and, 115–116, 116f
- Chiral centers
 designations for, 216–220, 218f, 218t
 of diastereomers, 224–225
 of geometric isomers, 226
- Chirality, 210–213, 211f
- Chlorambucil, 167f, 168, 168f
- Chloramphenicol, 271f, 274f
- Chloramphenicol sodium succinate, 147, 147f
- Chlorine
 aliphatic amines and, 64
 electronegativity of, 21, 22, 22t, 179t, 180
 SARs of, 318
- Chlorpheniramine, 180–181
- Chlorpromazine, 328, 328f, 340f
- Chlorpropamide, 329–330, 329f, 334
- Cholesterol, 18–19
 steroid nomenclature for, 9, 10f
- Chronic obstructive pulmonary disease (COPD),
 17–18, 31, 317
 homologation and, 338
- Ciclopirox olamine, 137t
- Cimetidine, 337
 pH and pK_a of, 106
- Ciprofloxacin, 72, 72f
 drug interactions of, 198–199
- Cis* isomers, 226–227, 227f, 228, 228f
- Classical isosteres, 334–335, 334t, 335f
- Clavulanate potassium, 137t
- Clindamycin
 hydrogen bonds of, 187–188, 187f
 molecular modification of, 330, 330f
 prodrug conversion of, 342, 343f
- Clomipramine hydrochloride, 137t
- Clonidine, 72, 72f
- Clonidine hydrochloride, 130f
- Clopidogrel
 covalent bonds of, 167f
 CYP2C19 and, 298
 rearrangement reactions of, 173, 173f
- Cocaine, 278
- Complexation, 199, 199f

Conformational isomers, 228–236, 229f–232f, 234f, 235f

Conformational restriction, 2
benefits of, 234–236, 234f, 235f
molecular modification and, 327–328, 327f
SARs and, 317–318

Conjugate base, 62

Conjugation, 280–297
acetylation, 292–293, 292f–294f
of amino acids, 288–290, 288f, 289f
of glucuronic acid, 281–285, 281t, 283f–285f
of glutathione, 290–292, 290f, 291f
methylation, 294–296, 295f, 296f
of sulfates, 285–287, 286f, 287f, 292

Copper, chelation of, 197, 197f

Covalent bonds, 166–173, 166t, 167f–173f
acylation and, 168–171, 169f–171f
alkylation and, 168, 168f
concerns with, 166–167, 167f
electrophilic functional groups and, 24
of inorganic salts, 129
ionization with, 174
phosphorylation and, 171–172, 172f
rearrangement reactions and, 173, 173f
types of, 167–173, 168f–173f

C-terminus, 177, 177f

Cyclizine, 325f

Cyclohexane, 4
chair-chair inversions of, 232
conformational isomers of, 232, 232f, 233
oxidation of, 257f

Cyclooxygenase, 32, 32f
acylation of, 170, 170f
conformational isomers of, 235, 235f
covalent bonds and, 166
enantiomers of, 222
ionic bonds on, 114

Cyclopentane, 4

Cyclopentylpropionic acid, 148f

Cyclophosphamide, 345–346, 345f

CYP2C9, 297–298, 298f

CYP2C19, 298, 300

CYP2D6, 298, 299f, 300, 300f

CYP3A4, 299–300, 361

Cysteine, 39
binding interactions of, 196t
glutathione conjugation and, 290–291
omeprazole and, 347, 347f

Cytochrome P450 (CYP450), 246–248, 247f, 248t, 249f
for alkene oxidation, 252f
for aromatic hydroxylation, 252f
for carbonyl group oxidation, 254–255, 255f

for hydroxyl group oxidation, 266–268, 266f–268f
ketone reduction and, 272f
metabolism and, 297–300
N-oxidation by, 263f, 264f, 265f
for *O*-dealkylation, 278
oxidative deamination by, 259f
for oxidative dehalogenation, 270–271, 271f
for sulfur oxidation, 268–270, 269f, 270f

Cytosine, 12, 13t

D

Debye forces, 188

Deconjugation, 279, 280f

Deoxyribofuranose sugars, 6, 6f

Deoxyribonucleic acid (DNA), 12
covalent bonds and, 166
electrophilic functional groups and, 24
functional groups on, 40–41, 41f
hydrogen bonds of, 184, 184f
molecular modification and, 330–331
sulfate conjugation and, 286

Dewick, P. M., 5, 13

Dexamethasone, 98

Diastereomers, 224–228, 224f–228f
enantiomers and, 224–225, 224f
geometric isomers and, 228, 228f

Diazepam, 65, 65f
aromatic hydroxylation of, 251f
conjugation of, 285
heparin and, 136f
oxidative *N*-dealkylation of, 259, 260f

β -dicarbonyl groups, 53–54, 55f, 140f
enantiomers of, 215
 pK_a of, 71t

Diclofenac, 32, 32f
amino acid conjugation of, 289f
conformational isomers of, 235, 235f
enantiomers of, 223f
SARs of, 318

Dicyclomine, 257f, 338, 339

Diethylstilbestrol, 228, 228f

1,4-dihydropyridine (1,4-DHP), 318–319, 318f

5 α -dihydrotestosterone, steroid nomenclature for, 9, 10f

Dipeptides, 10

Diphenhydramine, 325f

Diphenoxylate, hydrolysis of, 277f, 278

Dipole-dipole interactions, 27, 180–181. *See also*
Hydrogen bonds

charge transfer interactions as, 193–195, 194f, 195f
Dipole-induced dipole interaction, 188–190, 189f, 190f

Dipole interactions, 179–188, 179t, 183f–187f.

See also Hydrogen bonds

van der Waals interactions, 188–190, 189f, 190f

Disopyramide, 221, 221f

Disopyramide phosphate, 137t

Disulfide bond

of cysteines, 39

reductions of, 274

D/I designation, 8, 216–220, 218f, 218t

Dopamine

alpha/beta (α/β) designation of, 7f

methylation of, 294

Double bonds, 3–4

for conformational restriction, 327–328

Doxepin, 227–228, 227f

Doxycycline, 35, 35f, 322–323, 322f

DrugBank, 13

Drug interactions

chelation and, 198–199

of organic salts, 134–135, 135f, 136f

pH and, 326

pK_a and pH and, 116–117

SARs and, 323–326, 325f, 326f

Duloxetine, 272, 273f

Duration of action

of pharmacodynamic effects, 17

pK_a and pH and, 112–113, 113f

E

Easson, Leslie, 222–223

E isomers, 227–228, 227f

Electrolytes, 59

Electron donating functional groups, 23, 24f

sulfonamides and, 56

Electronegativity, 21–22, 22t

Electron withdrawing functional groups, 23, 24f

penicillin G and V and, 25–26, 25f, 26f

phenols and, 59–60

sulfonamides and, 56

Electrophilic functional groups, 24–26, 24f–26f

glutathione conjugation and, 291–292

sulfate conjugation and, 287f

Enalaprilat, 11, 12f, 18

enantiomers of, 213–215, 215f

SARs of, 319–320, 320f

Enantiomers, 8, 213–224, 214f, 215f, 218t, 221f–223f

designations for, 216–220, 218f, 218t

diastereomers and, 224–225, 224f

pharmacological and therapeutic differences

between, 220–224, 221f–223f

steric hindrance of, 223–224, 223f

Encainide, 264, 264f

Enflurane, 271f

Enol form, of β -dicarbonyl groups, 54

Enterohepatic circulation/recycling, 285

Enzymes. See also *specific types*

acidic functional groups in, 177–178, 177f

as biological targets, 17, 36

enantiomers and, 224

ionic bonds of, 176, 176f

metabolism and, 245

for oxidation, 246–249, 247f, 248t, 249f

sulfate conjugation and, 286

Epinephrine, 31, 31f

enantiomers of, 222–223, 222f

homologation of, 338

methylation of, 294

SARs of, 316–317, 317f

Epirubicin, 279f

Eplerenone, 72, 72f

Eprosartan, 328, 328f

Erythromycin, 133, 134f

Erythromycin stearate, 133

Esmolol, 275, 276f

Essentials of Foye's Principles, 13

Ester group, 140f

carbonyl group of, 20

of carboxylic acid, 147, 147f

electron withdrawing functional groups of,
23, 24f

as electrophilic, 24

as hydrogen bond acceptor, 183f

hydrolysis of, 276, 277f

lipophilic functional groups and, 28–29

organic salts and, 134

prodrug conversion of, 341–342, 342t

for water and lipid solubility, 146–149, 147f–149f

Estradiol, 59–60, 59f

SARs of, 321, 321f

steroid nomenclature for, 9, 10f

Estradiol valerate, 148, 148f

Estrone, 141, 141f, 287f

Estrone sodium sulfate, 61f

Estrone sulfate, 280f

Ether group, 140f

Ethers

charge transfer interactions of, 194f

CYP450 and, 268f

as hydrogen bond acceptor, 183f

oxygen of, 139

Ethinyl estradiol, 321f, 322

Ethylenediaminetetraacetic acid (EDTA), chelation
of, 197, 197f

Ethyl group, 277

Excitable membranes, 17

Ezetimibe

dipole-dipole interactions of, 181

hydrogen bonds of, 187, 187f

F

F β adrenergic receptors, 31

Fenofibrate, 147f, 148

hydrolysis of, 276, 277f

SARs of, 324t

Fenofibric acid, 147f, 148, 324t

Fenopropfen, 32, 32f

aromatic hydroxylation of, 251f

conformational isomers of, 235, 235f

Fexofenadine, 325f

First-pass metabolism, 299

Fischer, Hermann Emil, 216

Fischer projections, 216–217

Flavin monooxygenase (FMO), 248, 250f

N-oxidation by, 264f

for sulfur oxidation, 268–270, 268f, 269f

Fluconazole, 326, 326f

Fluocinolone acetonide, 150f

Fluorine

electronegativity of, 21, 22, 22t, 179t, 180

as hydrogen bond acceptor, 139, 183f

lipophilic functional groups and, 28

Fluoroquinolones, drug interactions with, 198–199,

325, 325f

Fluoxetine, 18

Flurbiprofen

enantiomers of, 221, 223f

pH and p*K*_a of, 103

Fluvastatin, 138t, 378–380

Fluvoxamine, 283f

Formaldehyde

methenamine and, 117

prodrug conversion of, 346–347, 346f

Fosamprenavir, 279f

Fosamprenavir calcium, 61f

Fosphenytoin, 342, 343f

Fosphenytoin sodium, 137t

Free acid, 129

Free base, 110, 133

Frovatriptan, 68, 68f

Fructofuranose sugars, 6, 6f

Fructose, 6, 6f

Fumarate, 226, 226f

Fumaric acid, 137t

Functional groups. *See also specific types*

on amino acids, 36–40, 37f

biological targets and, 31, 31f, 36

characteristics and roles of, 15–50

chemical properties of, 19–33

for COPD and asthma, 17–18

defined, 15–17

on DNA, 40–41, 41f

versus drug molecules, 72, 72f

electron donating, 23, 24f, 56

electronic effects of, 20–26, 21f–26f, 22t

electron withdrawing, 23, 24f, 25–26, 25f, 26f, 56, 59–60

electrophilic, 24–26, 24f–27f

hydrogen bonds of, 27–28, 28f

ionization of, 73–74, 109–110

molecular modification and, 328–331, 328f–331f

with nitrogen, 70–72, 71t, 72f

noncovalent bonds and, 174

nucleophilic, 24–26, 24f–27f, 29f, 30f, 60

on ribonucleic acid (RNA), 40–41

on RNA, 41f

solubility effects in, 26–30, 27f–30f

steric effects of, 30–33, 31f–33f

for water and lipid solubility, 149–151,

150f, 151f

Furanose rings, 6

Furan rings, 194f

Furosemide, 185, 185f

G

Gabapentin, 52–53, 53f, 63–64, 64f

Gauche conformation, 231, 231f

Gemfibrozil, 72, 72f

Gentamicin, 74f

cefepime and, 134–135, 135f

pH and p*K*_a of, 110, 110f

Geometric isomers, 226–228, 227f

diastereomers and, 228f

Glucocorticoids

hydrolysis of, 276, 277f

lipid solubility of, 148, 149f, 150, 150f

Glucopyranose sugars, 6, 6f, 7–8

Glucose, 6, 6f

alpha/beta (α/β) designation of, 7–8

Glucuronic acid, 281–285, 283f–285f

conjugation of, 281t

Glucuronide, 281t, 282–285, 283f–285f

Glutamic acid, 39

acidic functional groups in, 177, 177f

binding interactions of, 196t

ionization of, 178, 178f

Glutamine, 40

amino acid conjugation of, 288f, 289f

binding interactions of, 196t

Glutathione, 24
 aromatic hydroxylation of, 251, 252f
 conjugation of, 281, 281t, 290–292, 290f, 291f
 sulfate conjugation and, 286

Glyburide
 molecular modification of, 329–330, 329f
 pH and pK_a of, 107

Glyceraldehyde, 216

Glycine, 37
 amino acid conjugation of, 288f, 289f
 binding interactions of, 196t

Glycosides, 279f

Glycosidic bonds, 9, 9f

Gout, 75, 111–112

Graham Solomons, T. W., 5, 13

Grimm's Hydride Replacement Law, 331–334,
 331f, 332t

Guanabenz acetate, 137t

Guanidine group, 66–67, 67f, 140f
 in arginine, 116
 ionization of, 175t
 pK_a of, 71t, 116
 resonance delocalization of, 67

Guanine, 12, 13t

Guanosine monophosphate (GMP), 335, 336f

H

H₂ receptor antagonists, 117, 326, 336–337, 337f

Halcinonide, 150f

Halogens, 140f
 charge transfer reactions of, 195f
 electronegativity of, 22, 22t
 electron withdrawing functional groups of, 23, 24f
 as electrophilic, 24
 nonclassical isosteres of, 337t
 oxidative dehalogenation of, 270–271, 271f

Haloperidol, 136f

Haloperidol decanoate, 148, 148f, 149–150

Hemiacetal sugars, 6, 6f

Hemiketal sugars, 6, 6f

Henderson-Hasselbalch equation, 85–86, 88–92,
 89f, 100–108
 for captopril, 95, 96
 SARs and, 312
 for tamoxifen, 96

Heparin
 chemical antagonism of, 115–116, 116f
 drug interactions with, 135, 136f

Heterocyclic nitrogens, 183f

Heterocyclic rings
 charge transfer interactions of, 193–195, 194f, 195f
 numbering of, 5

pH and pK_a of, 102

Histidine, 40
 angiotensin I and, 11
 aryl-aryl stacking interactions of, 192–193
 aspartic acid and, 177, 177f
 binding interactions of, 196t
 cation- π interaction of, 193
 ionic bonds of, 176–177, 176f
 ionization of, 177, 177f

HMG-CoA reductase inhibitors, 138, 138t

Homocysteine, 39

Homologation, 338–341, 339f–341f

Human immunodeficiency virus (HIV) protease
 inhibitors, 383–385

Human immunodeficiency virus (HIV) reverse
 transcriptase inhibitors, 331

Hydralazine, 65, 65f, 66

acetylation of, 292, 292f

conjugation of, 283f

Hydrazide group, 68, 175t

Hydrazine group, 65–66, 65f, 66

carbidopa and, 51

as hydrogen bond acceptor/donor, 186f

Hydrobromic acid, 129

Hydrocarbon chains, 338

Hydrocarbon rings, 188–190, 189f, 190f

Hydrochloric acid, 128, 129, 137t

Hydrocortisone, 148, 149f

Hydrocortisone butyrate, 149, 149f

Hydrogen
 chirality of carbon and, 212
 electronegativity of, 179, 179t, 180
 Hydrogen bond acceptor, 28, 29f, 182–183, 183f, 186f
 fluorine as, 139

Hydrogen bond donors, 28, 29f, 182–183,
 183f, 186f

Hydrogen bonds, 181–187, 183f–187f
 doxycycline and tetracycline and, 35, 35f
 of functional groups, 27–28, 28f
 hydrophilic functional groups and, 139
 of hydroxyl group, 20, 131
 lactones and, 142
 metabolism and, 244, 245f

Hydrolysis, 275–279, 276f, 277f, 279f, 280f
 prodrug conversion and, 343

Hydrophilic functional groups, 26–28, 27f, 28f
 of bimatoprost, 143, 143f
 drug molecule analysis for, 139, 140f
 hydrogen bonds and, 139
 organic salts in, 131, 132f
 with ortho designation, 141
 for penicillin G, 150–151, 151f

- Hydrophobic functional groups, 28–30, 29f, 30
 drug molecule analysis for, 139, 140f
 ionic bonds of, 114, 114f
 van der Waals interactions of, 190–192, 191f
- 3-hydroxy-3-methylglutaryl CoA (HMG-CoA),
 315, 316f
- Hydroxylamine
 N-oxidation of, 263, 263f, 264
 reduction of, 274f
 sulfate conjugation of, 287f, 292
- Hydroxyl group, 140f
 in alendronic acid, 140, 141f
 aliphatic amines and, 64–65
 alpha/beta (α/β) designation of, 7–8
 aromatic rings for, 58–60, 58f, 59f
 carboxylic acid and, 74
 charge transfer interactions of, 194f
 chirality of carbon and, 211
 conjugation of, 284
 doxycycline and tetracycline and, 35, 35f
 electron withdrawing functional groups of, 23, 24f
 erythromycin and, 133, 134f
 as hydrogen bond acceptor/donor, 183f
 hydrogen bonds of, 20, 131
 ketone reduction and, 272f
 methylation of, 294
 noncovalent bonds of, 174
 as nucleophilic, 24
 oxidation of, 266–268, 266f–268f
 of phenol, 139
 phenyl rings and, 22–23, 22f
 of pravastatin, 142, 142f
 prodrug conversion in, 341
 resonance of, 20, 21f
 SARs of, 321, 321f, 322–323, 322f
 sulfate conjugation of, 287f
- Hypertension, 319, 359–362
- Hyperuricemia, 75
- Hypoxanthine, 335
- I**
- Ibandronate sodium, 74f
- Ibuprofen, 1
 alpha/beta (α/β) designation of, 7f
 enantiomers of, 221
- Imidazole ring
 charge transfer interactions of, 194f
 of histidine, 176–177
 ketoconazole and, 117
- Imide group
 as acidic functional group, 27f
 β -dicarbonyl groups and, 53, 55f
 nitrogen and, 70
 pH and pK_a of, 71t, 702
- Imine group, 65–66, 65f
 ionization of, 175t
 pK_a of, 71t
- Imipramine, 65f
- Indole rings
 aromatic heterocycles and, 68
 charge transfer interactions of, 194f
- Indomethacin, 285
- Induced dipole-induced dipole interactions, 10f,
 188–190, 189f
- Inductive effect, 22–23
 electron withdrawing functional groups and, 23
- Influenza, 18
- Ingold, Christopher, 217
- Inorganic salts, 129–131, 130f
 for lipid solubility, 146
- Intensity, of pharmacodynamic effects, 17
- Interferon-alpha, 343–344
- Intrinsic induction, 21
- Iodine, 22, 22t, 179t, 180
- Ion-dipole interactions, 180–181
 with amine, 131
 with hydrophilic functional groups, 26
 ionic bonds and, 175
- Ionic bonds, 175–179, 176f–178f
 of carboxylic acid, 32
 of inorganic salts, 129
 ion-dipole interactions and, 175
 pK_a and pH and, 114–115
- Ionization
 of acidic functional groups, 110, 174–175, 175t
 of basic functional groups, 110, 174–175, 175t
 chemical antagonism and, 115–116, 116f
 with covalent bonds, 174
 of functional groups, 73–74, 109–110
 of glutamic acid, 178, 178f
 of histidine, 177, 177f
 lipid bilayers and, 110
 of lipophilic functional groups, 113
 of penicillin V, 129
 of phenols, 113
 of thioridazine, 129
- Irbesartan, 328f
 conjugation of, 283f
 enantiomers of, 213, 214f
- Isavuconazole, 344, 344f
- Isavuconazonium sulfate, 344, 344f
- Isoleucine, 38
 binding interactions of, 196t
- Isomeric sugars, 7
- Isoniazid, 69f, 293, 293f

Isopropyl group

- biological target selectivity and, 31
- homologation and, 338
- prodrugs, 147f, 148

Isoproterenol, 31, 31f

- hydrogen bonds of, 183, 184f
- methylation of, 294
- SARs of, 317, 317f, 318f

Isosteres, 331–337, 331f, 332t, 333t, 334t, 335f–337, 337t

Isoxazole rings, 23, 24f

Itraconazole, 299–300

K

Keesom forces, 188

Ketoconazole, 117, 326, 326f

Keto form, of β -dicarbonyl groups, 54, 55f

Ketones

- charge transfer reactions of, 195f
- as hydrogen bond acceptor, 183f
- hydroxyl group and, 266–268, 266f–268f
- oxidative deamination of, 258
- reduction of, 272–273, 272f, 273f
- sugars and, 5–6

Ketoprofen

- aromatic hydroxylation of, 251f
- enantiomers of, 221, 222f

Ketose, 5–6

L

Labetalol

- diastereomers of, 225, 225f
- sulfate conjugation of, 287f

 β -lactams, 33, 33f. *See also specific drugs*

- acylation of, 169, 169f
- covalent bonds of, 167
- hydrolysis of, 278–279
- SARs of, 314–315, 314f, 315f, 320–321

Lactones, 142, 261, 262f

Lamivudine, 331, 331f

Langmuir, Irving, 331–332

Lansoprazole, 117

Lead. *See* Molecular modification

Lemke, 5

Leucine, 38

- binding interactions of, 196t

Levonorgestrel, 367–370

Levothyroxine, 59–60, 59f, 113, 113f

Lidocaine, 74f

- chain branching of, 341, 341f
- hydrolysis of, 275, 276f
- metabolism of, 245–246, 245f

Lincomycin, 330, 330f

Liothyronine, 59–60, 59f, 113, 113f

Lipid bilayers, ionization and, 110

Lipid solubility. *See also* Lipophilic functional groups

- drug interactions and, 326
- enhancement benefits to, 154
- metabolism and, 152–154, 152f, 153f, 244
- optimizing, 146–152, 147f–151f
- prodrug conversion and, 342t, 343
- SARs and, 312, 323
- water solubility and, 144–145, 145f

Lipophilic functional groups, 28–30, 29f, 30f

- drug molecule analysis for, 139
- homologation and, 338
- ionization of, 113
- organic salts in, 132–133, 132f
- pH and pK_a of, 113
- of simvastatin, 142, 142f

Lomustine, 213

London dispersion forces, 188

Losartan, 188–190, 189f, 256f

Lovastatin, 18–19, 19f, 138t

Lysine, 40

- binding interactions of, 196t
- cation– π interaction of, 193
- ionic bonds of, 176, 176f

M

Maleate, 226, 226f

Mechanism of action

- of busulfan, 24
- of pharmacodynamic effects, 17
- of thiazides, 117

Mechlorethamine, 345–346, 345f

Medicinal chemistry, 1

Mefenamic acid, 318

Meperidine, 74f

- oxidative *N*-dealkylation of, 259, 260f
- van der Waals interactions of, 189, 189f, 191, 192f

Meprobamate, 283f

6-mercaptopurine, 335, 336f

Metabolism, 243–310. *See also* Conjugation;

- Oxidation
 - affecting factors on, 297–300, 298f–300f
 - chirality of carbon and, 211
 - cytochrome P450 (CYP450) and, 297–300
 - enzymes and, 245
 - general concepts of, 244–246, 245f
 - hydrolysis, 275–279, 276f, 277f, 279f, 280f
 - lipid solubility in, 244
 - phase II of, 280–297

phase I of, 246–280
 of prodrugs, 246
 reduction, 272–275, 272f–275f
 solubility and, 152–154, 152f, 153f
 steric hindrance on, 33, 33f
 water solubility in, 244
meta designation, 4–5
 aromatic hydroxylation and, 250–251
 SARs and, 319
 Metaproterenol, SARs of, 317, 317f
 Metformin, 67f
 Metformin, guanidine group and, 67
 Methacholine, 18–19, 19f
 enantiomers of, 221, 221f
 Methadone, reduction of, 272, 273f
 Methdilazine, 340f
 Methenamine
 formaldehyde and, 117
 prodrug conversion of, 346–347, 346f
 Methionine, 39
 binding interactions of, 196t
 methylation of, 295f
 Methotrexate, 111
 Methotrexate, pH and pK_a of, 111
 Methoxy group
 electron donating functional groups and, 23, 23f
 electron withdrawing functional groups of, 23, 24f
 quinidine and, 68
 α-methyl acetic acids, enantiomers of, 223–224, 223f
 Methylation, 294–296, 295f, 296f
 conjugation of, 281t
 Methyl dopa, methylation of, 294
 Methyl dopamine, enantiomers of, 222f, 223
 α-methyl dopamine, alpha/beta (α/β) designation
 of, 7f
 Methylene group, 177
 chirality of carbon and, 212
 homologation with, 338–341, 339f–341f
 van der Waals interactions of, 192
 Methyl group, 18–19, 19f
 amino acid conjugation of, 290
 biological target selectivity and, 31
 charge transfer interactions of, 194f
 methylation of, 295
 morphine and, 34, 34f
 SARs of, 318
 in simvastatin, 142, 142f
 testosterone and, 34, 34f
 Methylsalicylate, 114
 Methyltestosterone, 321f, 322
 Methyl-tetrazole-thiomethyl (MTT) group, 323–324
 Metamide, 336, 337

Metoclopramide, hydrogen bonds of, 185–186, 185f
 Metoprolol
 chirality of carbon of, 210–212, 211f
 CYP2D6, 298, 299f
 Metoprolol tartrate, 137t
 Metronidazole, reduction of, 274f
 Minoxidil, sulfate conjugation of, 287f
 Mitoxantrone, 193
 Mixed-function oxidases, 246
 Molecular modification, 326–347
 conformational restriction and, 327–328, 327f
 functional groups and, 328–331, 328f–331f
 homologation, 338–341, 339f–341f
 of isosteres, 331–337, 331f, 332t, 334t,
 335f–337f, 337t
 prodrug conversion from active drugs, 341–347,
 342t, 343f–347f
 of sulfonyleureas, 329–330, 329f
 Monoethylglycinexylidide, 341, 341f
 Monomethylauristatin E (MMAE), 344, 345f
 Montelukast, 370–372
 Morphine
 conjugation of, 284, 285
 deconjugation of, 280f
 homologation of, 339, 339f
 hydrogen bonds of, 182
 methyl group and, 34, 34f
 Morphine sulfate, 130f
 Mutarotation, 7

N

Nabumetone, 346, 346f
N-acetyltransferase (NAT), 292–293, 292f
 Nadolol, 372–375
 Naphazoline, 66, 66f
 Naproxen, 1
 alpha/beta (α/β) designation of, 7f
 enantiomers of, 221, 222f
 SARs of, 324t
 Naproxen sodium, 130f
 SARs of, 324t
 Nateglinide
 conjugation of, 283f
 ionic bonds of, 176, 176f
N-dealkylation, 289–290
 Nefazodone, 195, 195f
 Neostigmine
 acylation of, 170–171, 171f
 hydrolysis of, 279f
 Neostigmine bromide, 72, 72f
 conformational isomers of, 234, 235f
 Newman projections, 230, 231f

Niacin, oxidative *N*-dealkylation of, 261, 262f

Nicardipine, oxidative *N*-dealkylation of, 260, 260f

Nifedipine, SARs of, 318, 318f

Nimodipine, acetylation of, 293, 294f

Nitrile group

- aromatic rings of, 20, 21f
- charge transfer reactions of, 195f
- electron withdrawing functional groups of, 23, 24f
- nonclassical isosteres of, 337t
- pK_a and pH of, 99
- resonance of, 20, 21f

Nitrofurantoin, 274, 274f

Nitrogen, 70

- alkyl group and, 62
- amidine group and, 66–67
- in aromatic heterocycles, 68–69, 68f, 69f
- chelation and, 197
- β -dicarbonyl groups and, 53, 54
- electronegativity of, 21, 22, 22t, 179, 179t
- guanidine group and, 67, 67f
- as hydrogen bond acceptor, 183
- N*-oxidation and, 262–265, 263f–265f
- resonance delocalization of, 67

Nitro group

- charge transfer reactions of, 195f
- electron withdrawing functional groups of, 23, 24f
- reduction of, 273–274, 274f
- SARs of, 318

Nitrone, *N*-oxidation of, 264, 264f

Nitroso, *N*-oxidation of, 263, 263f

Nitroso group, nitro group reduction and, 274, 274f

Nizatidine, 336

N-methyltransferase, 294

Nonclassical isosteres, 334, 335–336, 338

Noncovalent bonds, 166t, 173–200. *See also* Dipole interactions; Ionic bonds

- functional groups and, 174

Nonelectrolytes, 59

Nonsteroidal anti-inflammatory drugs (NSAIDs)

- acylation of, 170, 170f
- conformational isomers of, 235, 235f
- drug interactions with, 326
- enantiomers of, 221–224, 223f
- prodrug conversion of, 346, 346f
- reductions of, 275
- SARs of, 318, 318f, 319

Norethindrone, sulfate conjugation of, 287f

N-oxidation, 262–265, 263f–265f

NPH insulin

- for lipid solubility, 148
- as lipid-soluble, 133

N-terminus, ionic bonds of, 176, 176f, 177

Nucleic acids

- binding interactions of, 196t
- as biological targets, 17
- nomenclature for, 12, 13t

Nucleophilic functional groups, 24–26, 24f–26f

- alkylation of, 168, 168f
- glutathione conjugation and, 291
- methylation of, 296
- thiols and, 60

Nucleosides, 12

O

Octapeptides, 10, 11f

O-dealkylation, 277f, 278

Ofloxacin, 376–378

Olamine, 137t

Omega (ω) designation, 6–8, 7f

Omeprazole, 117

- chirality of carbon of, 210, 211f
- prodrug conversion of, 347, 347f

Orbital hybridization, 3–4

Organic salts, 131–135

- drug interactions of, 134–135, 135f, 136f
- esters and, 134
- in hydrophilic functional groups, 131, 132f
- for lipid solubility, 146
- in lipophilic functional groups, 132–133, 132f

Organophosphates, 171

Orphenadrine, 64, 64f

ortho designation, 4

- aromatic hydroxylation and, 251–252
- hydrophilic functional groups with, 141
- SARs and, 317–318, 318f

Oseltamivir, 18, 277f, 388–390

Oxazole rings, 194f

Oxidation

- of alicyclic carbon, 256–257, 256f, 257f
- of aliphatic carbon, 253–256, 254t, 255f–257f, 256–257
- of alkenes, 252, 252f, 253f
- of amides, 258–265, 259f, 260f, 262f–265f
- of amines, 258–265, 259f, 260f, 262f–265f
- of aromatic nitrogen, 258–265, 259f, 260f, 262f–265f
- of aromatic rings, 250–252, 251f, 252f
- of benzylic carbon, 253–256, 254t, 255f
- of carbon, 253–257, 254f–257f
- of carbonyl group, 254–255, 255f
- CPY450 for, 246–248, 247f, 248t, 249f
- enzymes for, 246–249, 247f, 248t, 249f
- of hydroxyl group, 266–268, 266f–268f
- in metabolism, 246–271

of sp^2 hybridized centers, 253–256, 254t, 255f
 of sulfur, 268–270, 269f, 270f
 Oxidative deamination, 258, 259f
 Oxidative dehalogenation, 270–271, 271f
 Oxidative *N*-dealkylation, 258–262, 259f, 260f, 262f
 Oxime, 186f
 2-oxoclopidogrel, 173, 173f
 Oxygen
 chelation and, 197
 β -dicarbonyl groups and, 54
 electronegativity of, 22, 22t, 179, 179t
 of ethers, 139
 as hydrogen bond donor, 183
 inductive effect of, 23
 Oxyphenbutazone, 54

P

Pamidronate disodium, 61f
para-aminobenzoic acid (PABA), 115, 115f
 HIV reverse transcriptase inhibitors and, 331
 SAR of, 313, 314, 314f
para designation, 4
 Paroxetine, 251f
 Partition coefficients
 for HMG-CoA reductase inhibitors, 138, 138t
 solubility and, 137–145, 138f, 140f–143f, 145f
 Penicillamine, 60, 60f
 chelation for, 197, 197f
 Penicillin G, 25–26, 25f, 26f
 alpha/beta (α/β) designation of, 7f
 hydrophilic functional groups for, 150–151, 151f
 SARs of, 324t
 Penicillin G benzathine, 75f, 76
 for lipid solubility, 148
 as lipid-soluble, 132
 SARs of, 324t
 Penicillin V, 25–26, 25f, 26f
 ionization of, 129
 salt form of, 128
 Pentazocine, 285, 296f
 Pentobarbital, 256f, 267f, 270f
 Peptides
 designations for, 9–12, 10f–12f
 functional groups and, 36–40, 37f
 Perindopril, 277f
 Peroxide group, 197
 pH
 antacids and, 117
 biological targets and, 114
 defined, 86–88
 drug interactions and, 116–117, 326

drug therapy and, 108–118, 109f–111f, 113f–116f
 duration of action and, 112–113, 113f
 enantiomers and, 215
 Henderson-Hasselbalch equation for, 85–86, 88–92, 89f, 100–108
 ionic bonds and, 114–115, 175
 ionization and, 174–175
 partition coefficients and, 138
 pK_a and, 92–98
 plasma proteins and, 113
 quantitative problems for, 98–108
 Rule of Nines for, 103–108
 SARs and, 312
 solubility effects of, 109–112, 109f–111f
 solving problems of, 85–125
 steric effects on, 86
 Pharmacodynamics effects, 17
 Pharmacogenomics, 297
 Pharmacokinetic effects, defined, 17
 Phase II metabolic transformations, 244
 Phase I metabolic transformations, 243
 Phenobarbital, 54, 55f, 73f
 pK_a and pH of, 101–102, 112
 Phenolic group, 58–60, 58f, 59f, 140f
 as acidic functional group, 27f
 aromatic hydroxylation of, 251–252
 aromatic rings of, 20
 charge transfer interactions of, 194f
 CYP450 and, 268f
 as hydrogen bond acceptor/donor, 183f
 hydroxyl group of, 139
 ionization of, 113, 175t
 pK_a of, 71t
 sulfate conjugation of, 287f
 Phenolic hydroxyl group, 30
 methylation of, 294–295
 sulfate conjugation of, 287f
 Phenol-*O*-methyltransferase (POMT), 294
 Phenothiazines
 chain branching of, 340–341, 341f
 conformational restriction of, 327–328
 Phenylalanine, 38
 angiotensin I and, 11–12, 12f
 aryl-aryl stacking interactions of, 192–193
 binding interactions of, 196t
 cation- π interaction of, 193
 van der Waals interactions on, 189, 189f
 Phenylephrine, aromatic hydroxylation of, 252, 252f
 Phenylethyl group, 19–20, 22–23, 22f
 Phenylpropanolamine, 296f

- Phenyl rings, 20
 charge transfer interactions of, 194–195, 194f, 195f
 electron donating functional groups and, 23, 23f
 hydroxyl group and, 22–23, 22f
- Phenytoin, 54, 55f
 chirality of carbon of, 211, 211f
 drug interactions with, 326
 prodrug conversion of, 342, 343f
- Phenytoin sodium, 130f
- Phosphates, 60–61, 61f
 binding interactions of, 196t
 hydrolysis of, 279f
 ionization of, 175t
 pK_a of, 71t
- 3'-phosphoadenosine-5'-phosphosulfate (PAPS), 285, 286f
- Phosphonates, 60–61, 61f
 ionization of, 175t
 pK_a of, 71t
- Phosphonic acid, 27f
- 5-phosphoribosyl 1-pyrophosphate (PRPP), 335, 336f
- Phosphoric acid, 129, 137t
- Phosphorus, 179t, 180
- Phosphorylation, 171–172, 172f
- Phosphoserine, 38–39
- Phytonadione (vitamin K), 140–141, 141f
- Pindolol, 74f
- Pioglitazone, 283f
- Piperidine rings, 192
- Pitavastatin, 138t
- Pitavastatin calcium, 137t
- Pivalic acid, 148f
- pK_a
 of acidic functional groups, 71–72, 72f
 of basic functional groups, 71–72, 72f, 86–87
 biological targets and, 114
 defined, 86–88
 drug interactions and, 116–117
 drug therapy and, 108–118, 109f–111f, 113f–116f
 duration of action and, 112–113, 113f
 Henderson-Hasselbalch equation for, 85–86, 88–92, 89f, 100–108
 ionic bonds and, 114–115, 175
 ionization and, 174–175
 pH and, 92–98
 plasma proteins and, 113
 quantitative problems for, 98–108
 Rule of Nines for, 103–108
 SARs and, 312
 solubility effects of, 109–112, 109f–111f
 solving problems of, 85–125
 steric effects on, 86
 structure activity relationships (SARs) and, 117
- Plasma proteins
 drug interactions and, 326
 pK_a and pH and, 113
 (+)/(-) Designation, 8
- Polyethylene glycol (PEG), 343–344
- Potassium hydroxide, 129, 137t
- Potassium penicillin V, 128, 129
- Pravastatin, 138t, 378–380
 hydroxyl group of, 142, 142f
 partition coefficients of, 142, 142f
 SARs of, 324t
- Pravastatin calcium, 130f
- Prazosin, 69, 69f
 conformational isomers of, 229–230, 230f
 SARs of, 319, 319f
- Prednisolone, 324t
- Prednisolone sodium phosphate, 146, 147f, 324t
- Preferred conformations, 230–231
- Prelog, Vladimir, 217
- Presystemic metabolism, 299
- Primaquine, 263, 263f
- Probenecid, 289f
- Procainamide, 65f, 334, 335, 341
 acetylation of, 293, 293f
 hydrolysis of, 278
 pK_a of, 91–92
- Procaine, 334, 335, 341
- Prochlorperazine, 264, 265f
- Prodrugs
 conversion from active drugs, 341–347, 342t, 343f–347f
 hydrolysis of, 276, 277f
 metabolism of, 246
 for water and lipid solubility, 146–149, 147f–149f
- Proline, 38
 binding interactions of, 196t
- Promethazine, 136f, 340f
- Prontosil, 110–111, 111f
- Propantheline, 338, 339
- Propionic acid, 148f
- Propranolol, 152–153, 152f
- Propylthiouracil, 283f
- Prostacyclin (PGI₂), 170
- Protamine sulfate, 115–116, 116f
- Proteins. *See also specific types*
 acidic functional groups in, 177–178, 177f
 as biological targets, 17, 36
 ionic bonds of, 176, 176f
 sulfate conjugation and, 286

Proton pump inhibitors, 117
 Protriptyline, 253f
 Pteridine rings, 195f
 Purine rings, 5
 Purines, 12, 13t
 Pyranose rings, 6
 Pyridine, 68
 Pyridine rings, 195f
 Pyridostigmine bromide, 234, 235f
 Pyrimidine rings, 5
 charge transfer reactions of, 195f
 Pyrimidines, 12, 13t
 Pyrrole rings
 aromatic heterocycles and, 68
 charge transfer interactions of, 194f
 as hydrogen bond acceptor/donor, 183f

Q

Quazepam, 270f
 metabolism of, 153, 153f
 partition coefficients of, 142–143, 142f
 SARs of, 324t
 Quetiapine fumarate, 137t
 Quinapril, 380–383
 Quinazoline rings, 195f
 Quinidine, 69f, 225, 225f
 Quinine, 225, 225f
 Quinoline, 68
 Quinoline rings, 195f

R

Raloxifene, 285, 285f
 Ramiprilat, 199, 199f
 Ranitidine, 269f, 336, 337
 Rearrangement reactions, 173, 173f
 Reduction, 272–275, 272f–275f
 Reinforced ionic bonds, 185, 185f
 Resonance
 of carbonyl group, 20, 21f
 of carboxylic acid, 20
 of β -dicarbonyl groups, 54
 electron withdrawing functional groups and, 23
 of hydroxyl group, 20, 21f
 of nitrile group, 20, 21f
 sulfonamides and, 56
 of thiols, 60
 Resonance delocalization, 67
 Ribofuranose sugars, 6, 6f, 7–8
 Ribonucleic acid (RNA), 12
 functional groups on, 40–41, 41f
 molecular modification and, 330–331

Ribose, 6, 6f
 alpha/beta (α/β) designation of, 7–8
 Rizatriptan, 289–290, 289f
 Rosuvastatin, 138t
 R/S designations, 8, 216–220, 218f
 Rule of Nines
 of carboxylic acid of PABA, 115
 for pK_a and pH, 103–108
 for uric acid, 112

S

S-adenosylmethionine (SAM), 25, 295f
 Salicylic acid, 73f
 amino acid conjugation of, 288f
 ionic bonds on, 114, 114f
 Salmeterol, 189–190, 190f, 339
 oxidative *N*-dealkylation of, 261
 Salts, 75–76, 75f. *See also* Inorganic salts;
 Organic salts
 from acidic functional groups, 136–137, 137t
 from basic functional groups, 75–76, 75f,
 136–137, 137t
 defined, 128–129
 solubility and, 127–164
 Saquinavir, 383–385
 Sawhorse projections, 230, 231f
 Schiff bases, 65
 Serine, 38–39
 binding interactions of, 196t
 enantiomers of, 217
 hydrogen bonds of, 182
 Simvastatin, 18–19, 19f, 138t
 hydrolysis of, 275, 276f, 278
 lipophilic functional groups of, 142, 142f
 methyl group in, 142, 142f
 partition coefficients of, 142, 142f
 SARs of, 324t
 Single bonds, 3–4
 S-methyltransferase, 294
 Sodium chloride, 128
 Sodium hydroxide, 128, 129, 137t
 Sodium phosphate, 146–147, 147f
 Sodium sulfacetamide, 75, 75f
 Solubility. *See also* Lipid solubility; Water solubility
 in functional groups, 26–30, 27f–30f
 metabolism and, 152–154, 152f, 153f
 partition coefficient and, 137–145, 138f,
 140f–143f, 145f
 of pH and pK_a , 109–112, 109f–111f
 Sorafenib, 386–388
 sp^2 hybridized centers, 253–256, 254t, 255f
 Stedman, Edgar, 222–223

- Stereochemical center, 7
- Stereochemistry
with biological targets, 175
chirality of carbon, 210–213, 211f
conformational isomers, 228–236, 229f–232f, 234f, 235f
diastereomers, 224–228, 224f–228f
drug actions and, 209–242
enantiomers, 213–224, 214f, 215f, 218f, 218t, 221f–223f
- Stereoisomers, 213
- Steric effects
with biological targets, 175
of functional groups, 30–33, 31f–33f
on pH and pKa, 86
- Steric hindrance
of enantiomers, 223–224, 223f
in hydrolysis, 278
on metabolism, 33, 33f
SARs and, 318
- Steroids, 9, 10f
- Streptomycin sulfate, 137t
- Structure activity relationships (SARs), 3, 311–326
absorption, distribution, metabolism, and elimination (ADME) and, 320–323
of ACE inhibitors, 320f
ADME and, 321f, 322f, 324t
adverse drug reactions and, 323–326, 325f, 326f
of angiotensin converting enzyme (ACE) inhibitors, 319–320
of beta-lactams, 314–315, 314f, 315f, 320–321
binding interactions and, 316–320, 317f, 318f, 320f
of doxycycline, 322–323, 322f
drug interactions and, 323–326, 325f, 326f
of HMG-CoA, 316f
of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA), 315
pK_a and, 117
of sulfisoxazole, 313, 314, 314f
of tetracycline, 322–323, 322f
"why" or "how" component of, 312–313
- Sucralfate, 110, 110f
- Sugars
binding interactions of, 196t
isomeric, 7
numbering of, 5–6, 6f
- Sulfacetamide, 75, 75f
- Sulfamethoxazole, 68, 68f
acetylation of, 293, 293f
pH and pK_a of, 110–111, 111f, 115, 115f
SAR of, 313
sulfate conjugation of, 287f
- Sulfanilamide
pH and pK_a of, 110–111, 111f
SAR of, 313
- Sulfates, 60–61, 61f
conjugation of, 281t, 285–287, 286f, 287f, 292
ionization of, 175t
pK_a of, 71t
- Sulfhydryl group, 60, 60f
complexation of, 199, 199f
electron withdrawing functional groups of, 23, 24f
glutathione conjugation and, 290–291
methylation of, 295
as nucleophilic, 24
- Sulfisoxazole
conjugation of, 283f
SAR of, 313, 314, 314f
- Sulfisoxazole diolamine, 131, 132f
- Sulfonamide group, 55–57, 56f, 140f
as acidic functional group, 27f
carbonic anhydrase and, 335, 337f
conjugation of, 283f
electron withdrawing functional groups of, 23, 24f
as hydrogen bond acceptor, 187
as hydrogen bond acceptor/donor, 186f
ionization of, 175t
nitrogen and, 70
nonclassical isosteres of, 337t
pH and pK_a of, 71t, 115, 115f
- Sulfone, 268, 269f
as hydrogen bond acceptor, 186f, 187
- Sulfonic acid, 27f
- Sulfonyl group
nitrogen and, 70
pH and pK_a of, 107
- Sulfonylureas, 55–57, 56f
as acidic functional group, 27f
drug interactions with, 326
as hydrogen bond acceptor/donor, 186f, 187
hydrolysis of, 279f
ionization of, 175t
molecular modification of, 329–330, 329f
pK_a of, 71t
- Sulfoxide group, 268, 269f
reductions of, 275, 275f
- Sulfur
chelation and, 197
chirality of carbon and, 210
electronegativity of, 179t, 180
methylation of, 295
oxidation of, 268–270, 269f, 270f
- Sulfuric acid, 129, 137t
- Sulindac, 275, 275f
- Sumatriptan, 56, 56f

T

- Tamoxifen
 CYP2D6 and, 300, 300f
 Henderson-Hasselbalch equation for, 96
 oxidation of, 252, 252f
 pK_a and pH of, 94–95, 96
 van der Waals interactions of, 189, 190f
Z isomer of, 227–228, 227f
- Tamsulosin
 conformational isomers of, 229, 229f
 SARs of, 319, 319f
- Tartaric acid, 137t
- Tautomeric forms, of β -dicarbonyl groups, 54
- t-butylacetic acid, 148f
- Telmisartan, 328f, 329
- Temazepam
 metabolism of, 153, 153f, 245–246, 245f
 partition coefficients of, 142–143, 142f
 SARs of, 324t
- Terbutaline, 18, 19, 317, 317f
- Testosterone
 methyl group and, 34, 34f
 SARs of, 321, 321f
 steroid nomenclature for, 9, 10f
- Tetracaine, 293, 294f
- Tetracycline, 35, 35f
 chelation of, 198, 198f
 drug interactions with, 325, 325f
 metabolism of, 244, 245
 SARs of, 322–323, 322f
- Tetrahydrozoline, 66, 66f
- Tetrazole, 329
 ionization of, 175t
 nonclassical isosteres of, 337t
 pK_a of, 71t
- Tetrazole rings, 58, 58f
- Thiazides, 75
 carbonic anhydrase and, 116, 116f
 mechanism of action of, 117
- Thienopyridine, 167
- Thiethylperazine, 268, 269f
- Thioamide, 186f
- Thiocarbonyl, 270, 270f
- Thioesters, 186f
- Thioethers
 as hydrogen bond acceptor, 183f
 oxidation of, 268
- Thio-inosine monophosphate (T-IMP), 335, 336f
- Thiols, 60, 60f
 electron withdrawing functional groups of, 23, 24f
 as hydrogen bond acceptor/donor, 183f
 ionization of, 175t
 pK_a of, 71t
- Thiopental, 270f
- Thiophene rings, 194f
- Thiophenol, 60, 60f
- Thioridazine, 129
- Thioridazine hydrochloride, 128, 129
- Thiourea group, 337
 as hydrogen bond acceptor/donor, 186f
 nonclassical isosteres of, 337f
- Threonine, 38–39, 180–181
 binding interactions of, 196t
- Thromboxane A_2 (TXA₂), 170
- Thymine, 12, 13t
- Ticlopidine, 64, 64f
- Timolol maleate, 132f
- Tirofiban, 56, 56f
- Tobramycin, 74f, 140, 141f
- Tocainide, 341, 341f
- Tolazamide, 257
- Tolmetin, 266–267, 266f
- Tolterodine, 193
- trans* conformations, 231, 231f
- trans* designation, 251
- Transfer RNA (tRNA), 198
- trans* isomers, 226–227, 227f, 228, 228f
- Transpeptidase, 169, 169f
- Transport proteins, 74–75
 enantiomers and, 224
 omeprazole and, 347, 347f
- Triamcinolone, 150, 150f
 acetone and, 150
 SARs of, 324t
- Triamcinolone acetonide, 150, 324t
- Trientine, 197, 197f
- Trifluoperazine, 340f
- Trifluoroethyl group, 142
- Trifluoromethyl group, 139, 143, 270
- Trimethadione, 54, 55f
- Trimethoprim, 268f
- Trimethyllysine, 40
- Tripeptides, 10–11, 11f
- Triple bonds, 3–4
- Tromethamine, 137t
- Tryptophan, 38
 aryl-aryl stacking interactions of, 192–193
 binding interactions of, 196t
 cation- π interaction of, 193
- Tyrosine, 38–39
 aryl-aryl stacking interactions of, 192–193
 binding interactions of, 196t
 cation- π interaction of, 193
 hydrogen bonds of, 183, 184f

U

Uracil, 12, 13t

Urea group

- as hydrogen bond acceptor/donor, 183f
- nitrogen and, 70

Uric acid, 75

- in gout, 111–112
- pH and pK_a of, 111–112
- Rule of Nines for, 112

V

Valacyclovir, 277f

Valeric acid, 148f

Valine, 38

- binding interactions of, 196t

Van der Waals interactions, 188–190, 189f, 190f

Verapamil, 98, 109–110, 109f

Vitamin K (phytonadione), 140–141, 141f

W

Warfarin, 73f

- drug interactions with, 326
- enantiomers of, 213, 214f

metabolism of, 297–298, 298f

reduction of, 272, 273f

Water solubility. *See also* Hydrophilic functional groups; Hydrophobic functional groups

of catechol rings, 251–252, 252f

drug interactions and, 326

enhancement benefits to, 154

lipid solubility and, 144–145, 145f

in metabolism, 244

metabolism and, 152–154, 152f, 153f

optimizing, 146–152, 147f–151f

prodrug conversion and, 342t, 343

SARs and, 312, 323

Z

Zafirlukast, 56, 56f, 370–372

pH and pK_a for, 100

Zaleplon, 264, 265f

Zanamivir, 152, 152f, 388–390

Zidovudine, 331, 331f

Zileuton, 197–198, 198f

Z isomers, 227–228, 227f

Zwitterion form, 151

